Lidocaine Versus Bupivacaine for Sphenopalatine Ganglion Block
NCT ID: NCT05269147
Last Updated: 2022-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2022-03-01
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The sphenopalatine ganglion (SPG) is located in the cranial section of the autonomous nervous system; it is connected with the brain stem and the central nervous system (CNS) and bears unique characteristics favorable for the treatment of many painful syndromes involving the face and head. Sphenopalatine ganglion block (SPGB), along with general anesthesia (GA), is one of the regional anesthetic techniques used to reduce the need for systemic analgesia and provides relative hypotension with controlled heart rate that may lead to a better surgical field for endoscopic surgery. In addition, SPGB appears to shorten hospital stays and reduce narcotic requirements in the recovery area. SPGB with bupivacaine delivered repetitively appears to decreased postoperative pain and more satisfaction with the surgery for patients. Also, Bupivacaine usage in nasal surgery provides better analgesia at least in the first 8 hours period and does not cause more bleeding. On the other hand, SPGB with lidocaine was found to decrease the need for additional analgesics in the postoperative period, increase patient satisfaction, decrease the length of hospital stay, and as a consequence, reduce the rate of secondary infections. However, no previous studies have demonstrated the superiority of one drug over the other when performing an intranasal SPG block.
Aim of the work: To determine the efficacy of lidocaine versus bupivacaine for sphenopalatine ganglion block in patients undergoing endoscopic septoplasty.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ropivacaine and Bupivacaine in Sphenopalatine Ganglion Block in Sinus Surgery
NCT03013361
Prilocaine for Sphenopalatine Ganglion Block in Endoscopic Hypophysectomy
NCT07188987
Efficacy of Liposomal Bupivacaine Post Septorhinoplasty
NCT05964868
Bupivacaine 0.125% Versus Bupivacaine 0.25% in Superficial Cervical Plexus Block for Tympanomastoid Surgeries in Adults
NCT06381401
Lidocaine Infusion Versus Magnesium Infusion in Decreasing Fentanyl Requirements in Endoscopic Sinus Surgeries
NCT06966102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligible patients will be evaluated by:
Preoperative:
Explanation of visual analog scale will be done to patients (the VAS consists of a straight, vertical 10-cm line; the bottom point represented "no pain" = (0 cm) and the top "the worst pain you could ever have" = (10 cm).
Randomization:
All patients fitting the inclusion criteria will be randomly allocated using computer-generated numbers into one of three groups. Labeled slips will be put in serially numbered opaque and sealed envelopes. They will be opened when an eligible patient will be enrolled by an independent worker, not worked in the study.
Group A (20 patients): patients will receive standardized general anesthesia + SBGB with normal saline.
Group B (20 patients): patients will receive standardized general anesthesia + SBGB with lidocaine 2% Group C (20 patients): patients will receive standardized general anesthesia+ SBGB with bupivacaine 0.5%
All patients will not receive anything per oral for at least 6 hours before a procedure. On arrival at the operation theatre, standard monitoring will be connected. Mean blood pressures (MBP), heart rate (HR) will be measured before the block (0 min.) and then every 10 minutes after the block till recovery time.
The patients will be received standardized GA protocol as follows:
1. Induction with propofol (1-2 mg/kg body weight),
2. Atracurium as a muscle relaxant (1 mg/kg body weight),
3. Isoflurane as a volatile anesthetic agent in 50% O2 and air, and
4. Analgesia with fentanyl (1 microgram/kg body weight). The total doses of fentanyl that were used during the operation will be recorded.
The patient will be evaluated intraoperatively and postoperatively for :
The Scoring criteria for an intraoperative surgical field using Fromme ordinal scale:
0 No bleeding
1. Slight bleeding but no suctioning of blood required
2. Slight bleeding with occasional suctioning required; surgical field not threatened
3. Slight bleeding with frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed
4. Moderate bleeding with frequent suctioning required; bleeding threatens the surgical field directly after suction is removed
5. Severe bleeding with constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery not possible
Postoperative Post-operative pain will be questioned by an anesthesiologist with a Visual Analog Scale (VAS) (0 = no pain, 10 = most severe pain) at the 30th minute(t1), 1st hour(t2), 4th hour (t3), 12th hour (t4) and 24th hours (t5) and analgesia was managed according to the VAS scores. If the VAS score is ≥ 4, the patient will be given rescue analgesia in the form of intravenously Pethidine 50mg.
The data on Postoperative nausea and vomiting will be collected by direct questioning by the anesthesiologist at the same time as pain score assessment. If there is 1 min between the episodes of vomiting, each one will be considered a separate episode. Every episode of vomiting will be scored as 1 point and the total score will be calculated after 24 hours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Postoperative Pain-free duration (minutes) will be recorded from the time of extubation to the first postoperative analgesic request when VAS ≥ 4 is the primary outcome.
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SBGB with normal saline
patients will receive standardized general anesthesia + SBGB with normal saline.
Sphenopalatine Ganglion Block (SPGB)
The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.
The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.
The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.
SBGB with lidocaine 2%
patients will receive standardized general anesthesia + SBGB with lidocaine 2%
Sphenopalatine Ganglion Block (SPGB)
The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.
The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.
The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.
SBGB with bupivacaine 0.5%
patients will receive standardized general anesthesia+ SBGB with bupivacaine 0.5%
Sphenopalatine Ganglion Block (SPGB)
The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.
The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.
The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sphenopalatine Ganglion Block (SPGB)
The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.
The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.
The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. American Society of Anesthesiologists class I and II
Exclusion Criteria
2. patients under the age of 18
3. Patients have systemic or bleeding disorders
4. patients who disincline to participate in the study
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huda Fahmy Mahmoud, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Huda Fahmy Mahmoud, PhD
Assistant professor of Anaesthesia and Intensive Care department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
huda F fahmy
Role: PRINCIPAL_INVESTIGATOR
Aswan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huda Fahmy
Aswān, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
506/1/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.